Status:
COMPLETED
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Guerbet
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of throm...
Eligibility Criteria
Inclusion
- Patients must be more than 18 years of age
- referred for coronary angiography and on dual anti-platelet therapy (aspirin and clopidogrel).
Exclusion
- on warfarin
- on low molecular weight heparin within 12 hours of coronary angiography or unfractionated heparin with activated clotting time \>150 at time of procedure -on cilostazol
- on persantine
- on non- steroidal anti-inflammatory medications (ibuprofen/motrin/advil, naproxen/aleve, indomethacin, sulindac, etodolac, diclofenac, celecoxib) within 72 hours of procedure
- on prasugrel (not an exclusion criteria for ST-segment elevation myocardial infarction registry
- undergoing coronary angiography via radial access
- undergoing planned diagnostic coronary angiography only
- unable to tolerate dual anti-platelet therapy
- with known allergy to CM
- received CM within 24 hours of coronary angiography
- on dialysis
- do not consent or are unable to give consent
- are participating in another competing study.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01848899
Start Date
February 1 2013
End Date
November 1 2014
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016